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ABSTRACT
Background Cardiovascular disease is the leading 
cause of death during pregnancy with thoracic aortic 
dissection being one of the main causes. Thoracic aortic 
disease is commonly related to hereditary disorders and 
congenital heart malformations such as bicuspid aortic 
valve (BAV). Pregnancy is considered a high risk period in 
women with underlying aortopathy.
Methods The ESC EORP Registry Of Pregnancy And 
Cardiac disease (ROPAC) is a prospective global registry 
that enrolled 5739 women with pre- existing cardiac 
disease. With this analysis, we aim to study the maternal 
and fetal outcome of pregnancy in women with thoracic 
aortic disease.
Results Thoracic aortic disease was reported in 189 
women (3.3%). Half of them were patients with Marfan 
syndrome (MFS), 26% had a BAV, 8% Turner syndrome, 
2% vascular Ehlers- Danlos syndrome and 11% had 
no underlying genetic defect or associated congenital 
heart defect. Aortic dilatation was reported in 58% of 
patients and 6% had a history of aortic dissection. Four 
patients, of whom three were patients with MFS, had 
an acute aortic dissection (three type A and one type B 
aortic dissection) without maternal or fetal mortality. 
No complications occurred in women with a history of 
aortic dissection. There was no significant difference in 
median fetal birth weight if treated with a beta- blocker 
or not (2960 g (2358–3390 g) vs 3270 g (2750–3570 g), 
p value 0.25).
Conclusion This ancillary analysis provides the largest 
prospective data review on pregnancy risk for patients 
with thoracic aortic disease. Overall pregnancy outcomes 
in women with thoracic aortic disease followed 
according to current guidelines are good.
INTRODUCTION
Aortic complications during pregnancy are particu-
larly a concern in women with underlying connec-
tive tissue diseases such as Marfan syndrome 
(MFS), vascular Ehlers- Danlos syndrome (vEDS), 
Loeys- Dietz syndrome (LDS) and SMAD3 aortop-
athy, but also women with Turner syndrome (TS) 
and congenital heart malformations like bicuspid 
aortic valve (BAV) may be more prone.1 2
Data obtained from the GenTAC registry on MFS 
show a significantly higher aortic dissection rate of 
5.4 per 100 person‐years during pregnancy and the 
postpartum period compared with a non- pregnancy 
dissection rate of 0.6 per 100 patient‐years.3 
However, data on the immediate and long- term 
effects of pregnancy on aortic outcome are not 
uniform due to publication and ascertainment 
biases, reports on small sample sizes and inclusion 
of women in whom dissection was the first presen-
tation of the underlying disease.1 3
Multiple factors impact the aorta during preg-
nancy. Increased haemodynamic stress and struc-
tural changes of the vascular wall may weaken the 
aortic wall in pregnant women with aortopathies.4–8 
The increased risk for aortic complications persists 
in the postpartum period, but clear management 
guidelines for this period are lacking.
Current guidelines advocate the use of beta- 
blockers in women known with underlying aortic 
disease throughout pregnancy to prevent complica-
tions, but the evidence supporting this is weak and 
the effect on fetal growth needs further research.9 
Atenolol has been associated with higher rates of 
fetal growth retardation. In contrast, metoprolol, 
labetalol, bisoprolol, propranolol and celiprolol 
in case of vEDS may be used safely during preg-
nancy, although caution with regard to fetal growth 
remains warranted.9
Use of large prospective datasets can help in 
addressing these specific issues and in determining 
the impact of pregnancy in women with aortic 
disease. In 2007, the Registry Of Pregnancy And 
Cardiac disease (ROPAC) was established by the 
EURObservational Research Programme (EORP) 
of the European Society of Cardiology (ESC) in 
order to provide contemporary information on the 
impact of pregnancy on a wide range of cardiovas-
cular diseases. With this ancillary analysis, we aim 
to study the pregnancy outcome of women with 
thoracic aortic disease.
METHODS
The rationale and design of the ROPAC have been 
described previously.10 In brief, the registry started 
in January 2007. Women with structural heart 
disease from 60 hospitals in 28 countries (both 
developed and developing countries) were enrolled. 
It collected the following data relating directly 
to the pregnancy: age at conception, cardiovas-
cular complications, obstetric complications, fetal 
complications, medication use, pregnancy duration 
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In this substudy, we focus on patients with aortic disease 
including (1) women with known heritable thoracic aortic 
disease (HTAD) in particular MFS, vEDS or TS or with BAV 
(not associated with one of the former conditions) with and 
without aortic dilatation/dissection and (2) women without one 
of the prespecified HTAD or BAV, but with aortic dilatation or 
previous aortic dissection, grouped under the term ‘Thoracic 
Aortic Dilatation/Dissection—TAD’. Because no specification 
of the exact location of aortic dilatation was requested in the 
questionnaires, we used the term ascending aorta throughout 
the paper referring to the ascending part of the thoracic aorta 
comprising both the root and tubular ascending aorta. No cut- 
off values for aortic dilatation were given in the questionnaires 
where the indication of aortic dilatation was left to the discretion 
of the including physician.
The following endpoints were studied: death; cardiovascular 
events: aortic dissection (type A and B), need for aortic surgery 
or intervention; obstetric complications: pregnancy- induced 
hypertension, (emergent) caesarean section (CS), premature 
birth and small for gestational age.
Details on ethical approval have been described previously.10
Statistical analysis
. Data are presented as mean values and SD if normally distrib-
uted and as median with IQR if skewed. Categorical data are 
presented as count divided by the total number of valid/available 
data. Differences in variables between diagnostic groups were 
evaluated by Student’s t- test, Mann- Whitney U test, analysis of 
variance, Kruskal- Wallis test and χ2 test where appropriate. Data 
analyses were performed with SPSS V.27.0. A p value of <0.05 
(two- sided test) was considered significant. Complete- case anal-
ysis was performed.
Patient and public involvement
Patients were not involved in the design, conduct, reporting or 
dissemination plans of our research.
RESULTS
Baseline characteristics
Thoracic aortic disease was reported in 189 out of 5739 women 
(3.3%) included in the registry from 2007 until 2018. More 
than half of these were patients with MFS followed by patients 
with BAV. Prior to pregnancy, ascending aortic dilatation was 
documented in 81 patients, in 49 cases no data were available 
(tables 1 and 2). Eleven patients had a history of aortic dissec-
tion—10 type A dissections (5 patients with MFS and 5 patients 
with TAD of which 2 had a traumatic dissection) and 1 type 
B dissection in a patient with vEDS. Data on the extent of the 
dissection and type of surgery was not available. One patient 
with vEDS underwent stenting for a ruptured superior femoral 
artery 1 year before pregnancy. Seventeen women underwent a 
valvular intervention prior to pregnancy of which seven had a 
mechanical valve (one mitral and six aortic valves (one Bentall)). 
In five patients, prior valve sparing ascending aortic replacement 
was indicated in the questionnaire.
Data on left ventricular function were reported in 119 cases 
of which 3 (2.5%) had a decreased ejection fraction prior to 
pregnancy. Two of these had a mildly impaired ejection fraction 
of 49% and 50%, respectively (one patient with MFS and one 
patient with TAD) and one patient with MFS had a moderate 
reduced ejection fraction of 35% treated with furosemide and a 
beta- blocking agent preconception.
Forty- nine per cent (20/41) and 51% (21/41) of the women 
with MFS known to have aortic dilatation were treated with 
a beta- blocking agent preconception and during pregnancy, 
respectively. Two out of the four included patients with vEDS 
were on beta- blockers (but none on celiprolol). Five women 















Age (median (IQR)) 29.1 (25.4–32.8) 31.1 (25.4–34.3) 30.2 (27.6–34.3) 28 31.1 (28.5–36.5) 31.5 (29–36.9) 0.17
Nulliparity 57/100 (57%) 18/48 (38%) 10/16 (63%) 2/4 (50%) 12/20 (60%) 99/188 (53%) 0.18
Arterial hypertension 12/97 (12%) 3/48 (6%) 4/16 (25%) 1/4 (25%) 4/19 (21%) 24/184 (13%) 0.33
Smoking
(current- former)
4-10/76 1-6/36 0-3/15 1-0/4 0-0/13 6-19/144 0.32
BMI (median (IQR)) 22 (20.4–24.7) 25.3 (21.9–30.7) 27.3 (24.3–30.8) 22.4 (20–29.4) 24.5 (22.2–26.5) 24.5 (22.2–26.5) 0.01
Emerging country 19/100 (19%) 18/49 (37%) 0/16 0/4 3/20 (15%) 40/189 (21%) 0.01
Aortic dilatation 41/59 (69%) 24/42 (57%) 1/16 (6%) 0/3 15/20 (75%) 81/140 (58%) <0.001
Dimension AA in mm (median (IQR)) 40 (35–45) 42 (40–44.3) 42 (42–42) / 41.5 (39.3–46.8) 42 (38–45) 0.68
Prior aortic dissection 5/100 (5%) 0/42 0/16 1/4 (25%) 5/20 (25%) 11/182 (6%) <0.001
  A 5 5 10/11
  B 1 1/11
  BB 4/5 1/1 2/2
BAV 4/96 (4%) 49 1/16 (6%) 0/4 0 54/185 (29%) <0.001
Valvular intervention 9/34 (26%) 6/17 (35%) 0/3 0/1 2/9 (22%) 17/64 (27%) 0.92
  Aortic 4 (1M, 1B, 2?) 6 (3M, 1B, 2R) / / 2 (2M) 12 (6M, 2B, 2R, 2?)
  Mitral 5 (1M, 1B, 3?) / / / / 5 (1M, 1B, 3?)
Treatment
  BB 27/54 (50%) 5/18 (28%) 4/7 (57%) 2/2 (100%) 6/10 (60%) 44/91 (48%) 0.037
  ACE- I 1/49 (0.02%) 1/18 (0.06%) 0/7 0/3 1/13 (0.08%) 3/90 (0.03%) 0.34
  ARB 1/47 (0.02%) 0/18 0/7 0/2 0/13 1/87 (0.01%) 0.56
  Diuretics 1/49 (0.02%) 0/18 0/7 0/3 0/13 0/90 0.93
  VKA 4/17 (24%) 4/8 (50%) 0/1 0/0 1/7 (14%) 9/33 (15%) 0.59
Categorical variables are presented as count divided by the total number of valid/available data and percentages between brackets.
?, unknown; AA, ascending aorta; ACE- I, ACE inhibitor; ARB, angiotensin receptor blocking agent; B, bioprosthesis; BAV, bicuspid aortic valve; BB, beta- blocking agent; IQR, interquartile range; M, mechanical valve; MFS, Marfan syndrome; OAC, oral 
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were on atenolol during pregnancy, the other women (of whom 
we have data) were treated with propranolol, labetalol, bisopr-
olol, celiprolol or metoprolol (56/91).
In total, nine women were treated with oral vitamin K antag-
onists, seven of which had a mechanical valve, the indication in 
two women was unknown. Demographic characteristics for each 
diagnostic group and for patients with or without aortic dilata-
tion are described in tables 1 and 2, respectively.
Cardiovascular complications
Four patients (2%) had an acute aortic dissection during preg-
nancy or in the postpartum period. Three were type A dissec-
tions requiring urgent surgical intervention and one type B 
aortic dissection that was treated conservatively. There was no 
maternal mortality. The patient with the type B dissection had 
known MFS and was treated with beta- blockers before and 
throughout pregnancy. Her ascending aorta was moderately 
dilated up to 43 mm prior to pregnancy with a small insignificant 
increase of the diameter of 2 mm measured by echocardiography, 
descending thoracic aortic dimensions were not available. She 
presented with a type B aortic dissection in the third trimester. 
The three patients with type A dissections were not known with 
MFS or aortic dilatation prior to pregnancy and were thus not 
under medical attention. In two of them, the diagnosis of MFS 
was made following the acute event. One of them presented 
with dissection 1 week postpartum (aortic diameter not known) 
and the second one presented at 37 weeks of gestation, with 
an ascending aortic diameter of 55 mm. The last patient expe-
rienced a type A aortic dissection at an ascending aortic diam-
eter of 60 mm at 26 weeks of gestation. Data are summarised in 
table 3.
Obstetric and fetal outcome
Overall, we observed a high CS rate of 63% (86/137), but it 
was not performed more in women with aortic dilatation versus 
women with normal aortic dimensions (p=0.37). Half (29/58) 
of the patients with MFS underwent an elective CS and 16% 
(9/58) urgent CS, (one patient with type A and one with type B 
aortic dissection, one due to aortic dilatation, five for obstetric 
reasons) . All patients with vEDS (4/4) underwent an elective 
CS and 69% (11/16) of the women with TS had a CS (7 elective 
and 4 urgent for non- cardiac reasons). All but one patient with 
previous aortic dissection had a CS of whom two urgent (one 
because of fetal distress and one for unknown reason).
No significant difference of pregnancy- induced hyperten-
sion or pre- eclampsia was noticed between the different disease 
groups (total of four women with pregnancy- induced hyper-
tension and four with pre- eclampsia, p=0.68 and p=0.85, 
respectively).
There were no fetal deaths. The median gestational age was 38 
weeks (37–39 weeks). Median birth weight was 2980 g (2660–
3450 g) and median birth weight centile11 50th (22–77.5th). 
There was no significant difference in birth weight and in birth 
weight centile in women treated with a beta- blocking agent 
compared with untreated women (2960 g (2358–3390 g) vs 
3270 g (2750–3570 g), p value=0.25 and 46.5th (12.5–76th) vs 
44th centile (19.5–69th), p value=0.96). No significant differ-
ences were found in rates for intrauterine growth retardation or 
preterm birth.
DISCUSSION
The purpose of the ROPAC registry was to study maternal and 
fetal outcomes in pregnant women with structural and isch-
aemic heart disease, pulmonary arterial hypertension and aortic 
disease. It is the largest prospective dataset to date. Pregnancy 
outcomes collected over a 10- year period in 5739 pregnancies 
were recently published.12 Patients with aortic disease consti-
tuted a relatively small subgroup within this registry.
The spectrum of thoracic aortic disease included in ROPAC 
was broad. Half of the women included were patients with MFS 
who had the highest rate of cardiovascular complications during 
pregnancy and peripartum period. Despite this, the rate of aortic 
dissection was low (3/100) in those with MFS and no admis-
sions for congestive heart failure were reported. All three aortic 
dissections in the patients with MFS occurred during the last 
trimester or shortly postpartum underscoring the risk for aortic 
dissection during the peripartum period.3 13 14 Only one of these 
three patients was known to have MFS prior to pregnancy. This 
Table 2 Baseline characteristics (prior to pregnancy) for patients 






Age (median (IQR)) 31.1 (28.1–34.3) 28.3 (25.7–32.3) 0.01
Nulliparity 42/81 (52%) 31/59 (53%) 0.59
Hypertension 9/81 (10%) 11/59 (19%) 0.18
Smoking (current- former) 1-10/62 3-7/54 0.51
BMI (median (IQR)) 23.7 (21.3–27.8) 24.4 (20.5–27.9) 0.98
Aortic diameter 42 (38–46.5) / /
Prior aortic dissection 3/81 (4%) 5/59 (8%) 0.36
  A 3 5
  B / /
BAV 27/81 (33%) 18/59 (31%) 0.72
Valvular intervention
  Aortic 8 (6M, 2R) 3 (1B, 2?)
  Mitral 5 (1M, 1B, 3?) /
Treatment
  BB 27/49 (55%) 14/27 (52%) 0.81
  ACE- I 3/55 (5,5%) 0/30 0.55
  ARB 0/47 1/25 (4%) 0.35
  Diuretics 1/55 0/30 1.0
  VKA 9/23 (39%) 0/9 0.035
Categorical variables are presented as count divided by the total number of valid/available data and percentages 
between brackets.
*Presence of aortic dilatation at moment of inclusion.
†Data on aortic dilatation were missing in 49 cases.
ACE- I, ACE inhibitor; ARB, angiotensin receptor blocking agent; BAV, bicuspid aortic valve; B, bioprosthesis; BB, beta- 
blocking agent; M, mechanical valve; R, valve repair; VKA, vitamin K antagonist.;
Table 3 Characteristics of patients presenting with aortic dissection during pregnancy
Pregnancy duration Type of dissection Diagnosis AA diameter
Therapy during pregnancy (prior to 
dissection)
Patient 1 26 weeks A ? 60 mm None
Patient 2 37 weeks B MFS (known) 45 mm BB
Patient 3 37 weeks A MFS (not known) 55 mm None
Patient 4 1 week pp A MFS (not known) ? None
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supports previous data that the awareness for preconception 
diagnosis of MFS is not common in women with pregnancy- 
associated aortic dissection.1 Data from the GenTAC registry 
showed a high prevalence of pregnancy- related aortic dissections 
in MFS of up to 7.4%, of which only 42% was aware of the 
diagnosis prior to pregnancy.3 Due to its retrospective design, it 
is assumable that there might have been an inclusion bias in the 
GenTAC registry. The same limitation may have played a role in 
ROPAC, although patients were prospectively included in the 
ROPAC registry three women were enrolled due to the occur-
rence of aortic dissection during index pregnancy.
Currently, there is no consensus at which dimension to 
recommend prophylactic aortic surgery preconception. Euro-
pean guidelines advise against pregnancy in patients with MFS 
with an aortic root diameter of >45 mm. Dissection rates 
below the threshold of 45 mm are low with prospective studies 
including patients with MFS with an aortic diameter ≤45 mm 
not reporting any cases of aortic dissections.14 A positive family 
history of dissection and rapid root growth >3 mm/y are 
however important risk factors to consider in the prepregnancy 
counselling.9
Unfortunately, even if preconception prophylactic aortic 
surgery is performed, this does not reduce the risk of vascular 
complications in other territories with a reported type B dissec-
tion rate in patients with MFS between 5.4% and 10% outside 
of pregnancy.15 16 This underscores the importance of imaging 
of the entire aorta prior to pregnancy in patients with MFS.9 
Type B dissections might occur irrespective of aortic root dimen-
sions.17 18 Data from a retrospective multicentre observational 
study reporting on pregnancy outcome in 151 patients with 
MFS with 258 pregnancies documented type B dissection in four 
patients (1.6%)—one of these patients had previously under-
gone aortic root replacement.19
The next largest patient population in this registry were 
women with BAV. Fifty- seven per cent had aortic dilatation 
(24/42), but no aortic complications occurred. The reported 
dissection rate during pregnancy in BAV patients ranges from 
0% to 4%.20 In total, 16 women with TS were included. Unlike 
in MFS, much less is known about the risk of pregnancy- related 
aortic complications in TS. Underlying congenital and acquired 
cardiovascular anomalies including BAV, coarctation of the aorta 
or aortic dilation were present in the majority of published cases 
of aortic dissection.21 In the current analysis, none of the 16 
women with TS experienced any cardiovascular event. Four 
had known preconception arterial hypertension and one had a 
BAV. Aortic dilatation was documented in one patient (with an 
ascending aorta diameter of 42 mm—aortic size index 21.6 mm/
m2).
Although last ESC guidelines contraindicated pregnancy in 
women with vEDS, four patients were enrolled, but no adverse 
events occurred.9 22 A retrospective analysis by Murray et al23 
reported a pregnancy- related maternal mortality rate of 4.9% 
per delivery. The prevalence of arterial dissection/rupture and 
uterine rupture was 9.2% and 2.6%, respectively.
Eleven per cent (20/189) of women were classified as ‘TAD’ 
because the underlying (genetic) diagnosis was not known. Post 
hoc, two of these TAD women were found to carry a pathogenic 
variant in a HTAD gene (one in SMAD3 and one in TGFBR2). 
It is possible that more of the women in the TAD group had 
an underlying genetic disorder explaining the presence of aortic 
dilatation/dissection in women of such a young age. Indeed, the 
presence of a pathogenic variant might predict a worse outcome, 
which is an important issue in the care for these patients with 
TAD.24
It is widely accepted to treat pregnant patients with MFS with 
beta- blockers. The 2018 pregnancy guidelines advise that beta- 
blocking agents should be considered throughout pregnancy in 
women with MFS and other HTAD and indicate that it is the 
preferred therapy in the case of coexistent arterial hyperten-
sion.9 In ROPAC, only 51% of pregnant women with MFS with 
aortic dilatation were treated with a beta- blocker. Birth weight 
tended to be lower when the mother had been treated with a 
beta- blocking agent, although this was not significant. Retrospec-
tive data from the UK demonstrate beta- blocker use in 64.2% of 
pregnant women with MFS with significant lower birth weight 
in patients on beta- blocking agents.19 Again, more prospective 
data are needed in order to draw definite conclusions.
There was a strikingly high rate of delivery by CS in this 
cohort (63%). All patients with vEDS had an elective CS as 
recommended by the guidelines. Most Turner women also had 
a CS for unclear indications, most presumably related to small 
body size of the mother. There are limited data on the effect 
of labour, specifically the active phase of labour on the risk of 
aortic dissection. Although CS is considered an attractive option 
as it is scheduled and changes of maternal haemodynamics are 
less compared with labour,4 vaginal delivery is the preferred 
mode of delivery in the majority of patients with cardiovascular 
disease due to lower risk of infection, bleeding and morbidity 
postpartum. Data recently published by Minsart et al18 suggested 
that vaginal delivery with rigorous pain control and avoidance 
of the Valsalva manoeuvre might be safe in women with MFS 
and an aortic root diameter ≤45 mm. However, further research 
addressing the mode and timing of delivery in TAD is necessary.
A dedicated ROPAC registry (ROPAC 3) for patients with 
aortic pathology has been initiated recently within the EORP 
with the aim of more accurately assessing the risks and outcomes 
during pregnancy. Some important issues, not yet included in 
ROPAC 1–2, are addressed such as data on aortic growth during 
pregnancy, dimensions of the distal aorta, details on genetic data 
and family history of aortic dissection.
CONCLUSION
The aortic dissection rate in women with thoracic aortic disease 
included in the ROPAC registry was low with good maternal 
and fetal outcomes. In three out of four women (75%) with 
aortic dissection, this occurrence was the first presentation of 
the underlying disease. This highlights the importance of early 
recognition of the diagnosis and preconception counselling in 
order to achieve better pregnancy outcome. Type A dissections 
in patients with MFS occurred at diameters above the 45 mm 
guideline recommendation, suggesting a relatively safe margin. 
However, this does not exclude the risk for type B dissections. 
Complete aortic imaging prior to pregnancy in patients with 
MFS by CT scanning or MRI is therefore advised. In this registry, 
the use of beta- blockers was surprisingly low with no significant 
effect on birth weight, whereas CS rates were high despite lack 
of supporting data. If a woman after preconception counselling 
decides to pursue pregnancy despite the risks, close proximity to 
a tertiary care centre with experienced obstetricians, anaesthesi-
ologists, cardiac surgeons and cardiologists with serial follow- up 
throughout pregnancy and the postpartum period with an indi-
vidualised plan for delivery is advised.
LIMITATIONS
ROPAC only includes a small fraction of all the women with 
MFS or other aortopathy. On the one hand, it may be biased by 
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of the aortopathy and on the other hand the sample is inher-
ently biased towards aortopathy patients who may inherently be 
considered more safe for pregnancy.
No genetic or HTAD- specific phenotypic data or details on 
family history were available in the database. It is likely that the 
diagnosis of MFS was based on clinical manifestations in some 
cases. Patients with genetic TAD entities, overlapping with MFS 
such as LDS or Aneurysm Osteoarthritis Syndrome may have 
inadvertently been included in the MFS group.
A threshold diameter to define aortic dilatation was not 
specifically defined in the questionnaires, it was only filled in 
as ‘dilatation yes/no’ and dimensions were often not provided. 
The number of patients with aortic dilatation may therefore be 
underestimated. Nor was the exact location of aortic dilatation 
(root or tubular ascending aorta) prespecified in the question-
naires—we used the term ‘ascending aorta’ to keep uniformity 
throughout the paper.
Another limitation is that a registry relies on correct and 
complete completion of questionnaires by the enrolling centres, 
data on baseline characteristics are unfortunately missing in some 
cases. Also data on previous aortic interventions and complica-
tions that may have occurred were often not provided.
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